Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died

Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide

If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19Continue reading

HybridChart Partners with athenahealth’s Marketplace Program to Bring Workflow Efficiency Solution to Rounding Physicians

Scottsdale, AZ – September 23, 2021 – HybridChart, a leading solutions provider for charge capture and workflow management, announced a partnership with athenahealth, Inc. joining the company’s Marketplace program. As part of the athenahealth® Marketplace, the EVOLVE product by HybridChart is a newly integrated application now available to athenahealth’s growing network of healthcare providers.Continue reading

Nationwide study of 295,000 brain cancer patients examines differences due to age and sex

Study by TGen and collaborators documents different outcomes for males and females at various ages

PHOENIX, Ariz. — Sept. 22, 2021 — Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous system (CNS) cancers.

Continue reading